

31-08-1999

14

Claims

1. Any drug composition consisting of immunosuppressants cyclosporins, FK506, or rapamycin and the bioactive peptides corresponding to the high-affinity binding/anti-lymphoproliferative site of interferons a,b,w,t, or recombinant proteins carrying one or more of the sequences corresponding to the structures of the bioactive peptides corresponding to the high-affinity binding/anti-lymphoproliferative site of the said interferons for the aim of amplification of immunosuppressants' activities to decrease their therapeutic dose, and as the consequence to avoid their undesirable side effects during organ and tissue transplantation or during treatment of cancers such as lymphomas, leukemias, myelomas, adenocarcinomas, autoimmune and chronic inflammatory diseases, such as rheumatoid arthritis, myasthenia gravis, lupus erythematosus, uveitis, hyperproliferative diseases, such as psoriasis vulgaris, wherein cyclosporins, FK506 or rapamycin can be exploited.

15

2. Compositions according to Claim 1 consisting of immunosuppressants cyclosporins, FK506 or rapamycin with one or more of the peptides containing at least 5 identical amino acid residues in the following table:

L	T	E	K	K	Y	S	P
	R	R	R	R	H	R	R
	Q	D	N	D		D	D
	M	L	M	N		N	L
		I	S	S		S	
	E	A	E			A	
	G	I					

20

wherein,

each amino acid residue in the top sequence can be modified with any of the amino acid residues under it.

25

According to C₁
n, and recom
peptide varia

According to C₁
ycin, and the
ically modified
macromolecul
ological condi

5
Sum B2

add B^3
 D^4

AMENDED SHEET